title: Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
abstract: Small unilamellar amphotericin B liposomes can reduce the toxicity of amphotericin B. In this study, we compared the physical, antifungal, pharmocokinetic, and toxic properties of two liposomal amphotericin B products, AmBisome and Anfogen, that have the same chemical composition but are manufactured differently. In vitro tests included determinations of the MICs and the concentrations causing the release of 50% of the intracellular potassium from red blood cells (K50 values) to assess toxicity. The 50% lethal dose (LD50) was evaluated by using uninfected C57BL/6 mice and single intravenous (i.v.) doses of 1 to 100 mg/kg of body weight. Multiple i.v. dosing over 18 days was performed with 0.5, 1.0, or 5.0 mg of Anfogen/kg or 1.0, 5.0, or 25 mg of AmBisome/kg to evaluate chronic toxicity. DBA/2 mice were infected intranasally with 2.5 x 10(6) Aspergillus fumigatus conidia, treated for 3 or 4 days with 3.0, 5.0, or 7.5 mg of Anfogen/kg or 3, 5, 7.5, or 15 mg of AmBisome/kg, and evaluated to assess the toxicity of the drugs to the kidneys (by measurement of blood urea nitrogen and creatinine levels and histopathology) and the drug efficacy. The median particle size was 77.8 nm for AmBisome and 111.5 nm for Anfogen. In vitro K(50) values were significantly lower for Anfogen (0.9 mug/ml) than for AmBisome (20 microg/ml), and the LD50 of AmBisome was >100 mg/kg, versus 10 mg of Anfogen/kg. There was significant renal tubular necrosis in uninfected and infected mice given Anfogen but no tubular necrosis in AmBisome-treated mice. AmBisome at 7.5 or 15 mg/kg was also more efficacious than 7.5 mg of Anfogen/kg for the treatment of pulmonary aspergillosis, based on survival and weight loss data and numbers of CFU per gram of lung. In conclusion, the efficacy and toxicity of these two liposomal amphotericin B products were significantly different, and thus, the products were not comparable.
authors.affiliation: Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave., Pomona, CA 91768, USA.
authors.forename: Jon A
authors.initials: JA
authors.lastname: Olson
authors.forename: Jill P
authors.initials: JP
authors.lastname: Adler-Moore
authors.forename: Gerard M
authors.initials: GM
authors.lastname: Jensen
authors.forename: Julie
authors.initials: J
authors.lastname: Schwartz
authors.forename: M Cecilia
authors.initials: MC
authors.lastname: Dignani
authors.forename: Richard T
authors.initials: RT
authors.lastname: Proffitt
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000254:growth & development; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D007668:Kidney / Q000187:drug effects; D007928:Lethal Dose 50; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D013172:Spores, Fungal / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B